## Clinical Context This patient presents with advanced HIV disease (CD4 <200 cells/µL) with clinical evidence of opportunistic infections (oral candidiasis, diarrhoea) and constitutional symptoms. The CD4 count of 120 cells/µL indicates WHO Stage 4 disease. ## Immediate Management Priorities **Key Point:** Patients with CD4 <200 cells/µL require urgent initiation of ART and simultaneous prophylaxis for opportunistic infections (OI prophylaxis) to prevent life-threatening complications. **High-Yield:** According to WHO and Indian National AIDS Control Organization (NACO) guidelines, ART should be initiated immediately in all HIV-positive individuals regardless of CD4 count, but patients with CD4 <200 cells/µL are at imminent risk of Pneumocystis jirovecii pneumonia (PCP), cryptococcal meningitis, and toxoplasmosis. ## Specific Prophylaxis Indicated | CD4 Count | Prophylaxis Required | |-----------|---------------------| | <200 cells/µL | TMP-SMX (or alternatives) for PCP | | <100 cells/µL | Add fluconazole for cryptococcal disease | | <50 cells/µL | Add azithromycin for MAC prophylaxis | **Clinical Pearl:** The presence of oral candidiasis at CD4 <200 cells/µL is a clinical marker for severe immunosuppression and warrants immediate ART initiation without delay for further confirmatory testing (which would already be done during initial diagnosis). **Mnemonic: START-OI** — Start ART immediately, Then Opportunistic infection prophylaxis, Add Resistant monitoring, Refer if needed, Track CD4 recovery. ## Why This Approach Delaying ART initiation to perform additional testing or referral in a patient with confirmed HIV and CD4 <200 cells/µL increases mortality risk. The CD4 count provided is already sufficient to guide management. Simultaneous initiation of OI prophylaxis prevents immune reconstitution inflammatory syndrome (IRIS) complications and death from preventable infections.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.